参考文献
[1]中华人民共和国国家卫生和计划生育委员会.胃癌规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(08):29—36.
[2]薛卫成,樊祥山,孟刚(整理).胃癌相关标志物免疫组化指标选择专家共识(2014)[J].临床与实验病理学杂志,2014(9):951—953.
[3]中国临床肿瘤学会抗肿瘤药物安全管理专家委员会,中国抗瘤协会胃癌专业委员会,肿瘤病理专业委员会.HER阳性晚期胃癌分子靶向治疗的中国专家共识(2016版)[J].临床肿瘤学杂志,2016,21(9):831—839.
[4]《胃癌HER—2检测指南(2016版)》专家组.胃癌HER—2检测指南(2016版)[J].中华病理学杂志,2016,45(8):528—532.
[5]秦叔逵,李进.阿帕替尼治疗胃瘤的临床应用专家共识[J].临床肿瘤学杂志,2015,20(9):841—847.
[6]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)恶性肿瘤患者营养治疗指南[M].北京:人民卫生出版社,2019.
[7]中国航癌协会胃癌专业委员会,中华医学会外科学分会胃肠外科学组.胃癌围手术期营养治疗中国专家共识(2019版)[J].中国实用外科杂志,2020,40(2):145—151.
[8]石汉平,许红霞,李苏宜,等.营养不良的五阶梯治疗[J].肿瘤代谢与营养电子杂志,2015,2(D):29—33.
[9]石汉平,李苏宜,王昆华,等.胃癌患者营养治疗指南[J].肿瘤代谢与营养电子杂志,2015,(2):37—40.
[10]日本胃病学会.胃癌处理规约[M].15版.东京:金原出版株式会社,2017.
[11]日本胃癌学会.胃癌治疗指南[M].5版.东京:金原出版株式会社,2018.
[12]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45 (2):228—247.
[13]Seymour L,Bogaerts J,Perrone A,et al.iRECIST:guidelines for response criteria for use in trials testing immunotherapeutics [J].Lancet Oncol,2017,18 (3):e143—e152.
[14]Xu G,Zhang W,Lv Y,et al.Risk factors for under-diagnosis of gastric intraepithelial neoplasia and early gastric carcinoma in endoscopic forceps biopsy in comparison with endoscopic submucosal dis-section in Chinese patients[J].Surg Endosc,2016,30 (7):2716—2722.
[15]Lauren P.The two histological main types of gastric carcinoma:diffuse and so-called intestinal-type carcinoma an attempt at a histo-clinical classification[J].Acta Pathol Microbio Scand,1965,64:31—49.
[16]Wang DS,Liu ZX,Lu YX,et al.Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer[J].Gut,2019,68 (7):1152—1161.
[17]Wang H,Li B,Liu Z,et al.HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer[J].Eur J Cancer,2018,88:92—100.
[18]Shitara K,Özgüroğlu M,Bang YJ,et al.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer (KEYNOTE—061):a randomised,open-label,controlled,phase 3 trial [J].Lancet,2018,392 (10142):123—133.
[19]Eto K,Hiki N,Kumagai K,et al.Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications[J].Gastric Cancer,2018,21 (4):703—709.
[20]Katat H.Mizusawa J.Katayama H,et al.Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (ICOG0912):a multicentre.non-inferiority.phase 3 randomised controlled trial[J].Lancet Gastroenterol Hepatol,2020,5 (2):142—151.
[21]Kang KC,Cho GS,Han SU,et al.Comparison of Billroth Ⅰ and Billroth Ⅱ reconstructions after laparoscopy-assisted distal gastrectomy:a retrospective analysis of large-scale multicenter results from Korea[J].Surg Endose,2011,25 (6):1953—1961.
[22]Bang YJ,Kim YW,Yang HK,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315—321.(https://www.daowen.com)
[23]Lee J,Lim DH,Kim S,et al.PhaseⅢtrial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J].J Clin Oncol,2012,30 (3):268—273.
[24]Yoshida K,Kodera Y,Kochi M,et al.Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage Ⅲ gastric cancer:interim analysis of JACCRO GC—07,a randomized controlled trial[J].J Clin Oncol,2019,37 (15):1296—1304.
[25]VAN HAGEN P,HULSHOF MC,VAN LANSCHOT JJ,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366 (22):2074—2084.
[26]Tepper J,Krasna MJ,Niedzwiecki D,et al.PhaseⅢ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26 (7):1086—1092.
[27]Khushalani NI,Leichman CG,Proulx G,et al.Oxaliplatin in combination with protractedinfusion fluorouracil and radiation:report of a clinical trial for patients with esophageal cancer[J].J Clin Oncol,2002,20 (12):2844—2850.
[28]Ajani JA,Mansfield PF,Crane CH,et al.Paclitaxel-based chemoradiotherapy in localized gastrie carcinoma:degree of pathologic response and not clinical parameters dictated patient outcome[J].J Clin Oncol,2005,23 (6):1237—1244.
[29]Ajani JA.Winter K,Okawara GS,et al.Phase Ⅱ trial of preoperative chemoradiation in patients-with localized gastric adenocarcinoma (RTOG 9904):quality of combined modality therapy and pathologic response[J].J Clin Oncol,2006,24 (24):3953—3958.
[30]Hall PS,Swinson D,Waters JS,et al.Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC):The GO2 phase Ⅲ trial[J].J Clin Oncol,2019,37 (Suppl 15):4006.
[31]Yamada Y,Higuchi K,Nishikawa K,et al.PhaseⅢ study comparing oxaliplatin plus S—1 with cisplatin plus S—1 in chemotherapy-naive patients with advanced gastric cancer[J].Ann Oncol,2015,26(1):141—148.
[32]Xu R.Wang ZQ,Shen L,et al.S—1 plus oxaliplatin versus S—1 plus cisplatin as firstline treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma:A randomized,phase 3 trial[J].J Clin Oncol,2019,37 (Suppl 15):4017.
[33]Lu Z,Zhang X,Liu W,et al.A multicenter,randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer[J].Gastric Cancer,2018.21 (5):782—791.
[34]Van Cutsem E,Moiseyenko VM,Tjulandin S,et al.Phase Ⅲ study of docetaxel and cispla-tin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24 (31):4991—4997.
[35]Wang J,Xu R,Li J,et al.Randomized multicenter phase Ⅲ study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer[J].Gastric Cancer,2016,19 (1):234—244.
[36]Shitara K.Takashima A,Fujitani K,et al.Nab-paclitaxel versus solvent-based paclitaxel in patiens with previously treated advanced gastric cancer (ABSOLUTE):an open-label,randomised,non-inferiority,phase 3 trial[J].Lancet Gastroenterol Hepatol,2017,2 (4):277—287.
[37]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376 (9742):687—697.
[38]Ishigami H.Fujiwara Y,Fukushima R,et al.Phase Ⅲ Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S—1 Versus Cisplatin Plus S—1 in Patients With Gastric Cancer With Peritoneal Metastasis:PHOENIX-GC Trial[J].J Clin Oncol,2018,36 (19):1922—1929.
[39]Briead B,Auzolle C,Pozet A,et al.Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer:A retrospective AGEO multicentre study[J].Dig Liver Dis.2016.48 (4):441—445.
[40]Cho JH,Lim JY,Choi AR,et al.Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor[J].Cancer Res Treat,2015,47 (4):697—705.
[41]Smyth EC,Verheij M,Allum W,et al.Gastric cancer:ESMO Clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2016,27 (suppl 5):v38—49.
[42]Rachel S van der Post ,Ingrid P Vogelaar ,Fátima Carneiro,et al.Hereditary diffuse gastric cancer:updated clinical guidelines with an emphasis on germline CDH1 mutation carriers[J].Journal of medical genetics,2015.52 (6):361—374.
[43]Willem B de Boer ,Hooi Ee ,Marian P Kumarasinghe.Neoplastic lesions of gastric adenocarcinoma and preximal polyposis syndrome (GAPPS) are gastric phenotype[J].Am J Surg Pathol,2018,42 (1):1—8.